In the present study, a liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method was developed for the screening and the structural elucidation of the metabolites of ecabet bismuth in rat bile. Solid-phase extraction cartridges were used for sample pre-treatment and a gradient liquid chromatographic system composed of 10 mM ammonium acetate buffer and methanol was used for chromatographic separation on a Phenomenex Kromasil C18 column. The triple quadrupole mass spectrometer was employed to thoroughly detect and acquire the detailed MS/MS spectra of ecabet and its metabolites. By comparing the chromatographic retention behaviors, as well as the changes in molecular weight and full-scan MS/MS spectra of the potential metabolites with those of the parent compound, two main metabolites were identified as glucuronide conjugate of carbonylated ecabet (7-oxo-ecabet) and glucuronide conjugate of ecabet. Neither of the two metabolites have previously been reported in the literature. The metabolic pathways of ecabet in rat were also proposed in this paper.
Tanabe Seiyaku Co., Ltd, Tanabe Annual Report, October (1994).
2.
MonteleoneG.CaprioliF., “Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis”, Curr. Opin. Investig. Drugs8(5), 423–428 (2007).
3.
ShibataK.ItoY.HongoA.YasoshimaA.EndoT.OhashiM., “Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions”, Antimicrob. Agents Chemother.39(6), 1295–1299 (1995).
4.
ItoY.ShibataK.HongoA.KinoshitaM., “Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori”, Eur. J. Pharmacol.345(2), 193–198 (1998). doi: 10.1016/S0014-2999(97)01622-1
5.
MitsuyamaK.TomiyasuN.MasudaJ.YamasakiH.TsurutaO.SataM., “High affinity of ecabet sodium for inflamed colonic mucosa in ulcerative colitis”, Dig. Dis. Sci.52(6), 1442–1443 (2007). doi: 10.1007/s10620-006-9587-1
6.
LeeJ.H.KinJ.J.HahmK.B.LeeD.H.KinN.KinS.K.PrakJ.J.ChoiS.R.LeeJ.H.LeeS.T.LeeE.H.RheeJ.C., “Efficacy and safety of ecabet sodium on functional dyspepsia: A prospective, double-blinded, randomized, multi-center controlled trial”, World J. Gastroenterol.12(17), 2756–2761 (2006).
7.
OkuyamaK.SaitoN.KumeE.NotoT.NagasakiM., “Ecabet sodium prevents esophageal lesions induced by the reflux of gastric juice in rats”, Inflammopharmacology15(2), 90–94 (2007). doi: 10.1007/s10787-006-1538-0
8.
ItoY.FukushimaT.SugawaraY.TakaitiO.NakamuraS., “Metabolic fate of a new anti-ulcer drug (+)-(1R, 4aS, 10aR)-1, 2, 3, 4, 4a, 9, 10, 10a-octahydro-1, 4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). I. Disposition, metabolism and protein binding in rats and dogs”, J. Pharmacobiodyn.14(9), 533–546 (1991).
9.
ItoY.SugawaraY.TakaitiO.NakamuraS., “Metabolic fate of a new anti-ulcer drug (+)–(1R, 4aS, 10aR)-1, 2, 3, 4, 4a, 9, 10, 10a-octahydro-1, 4a-dimethyl-7-(1-methylethyl)-6-sulfo-1-phenanthrene carboxylic acid 6-sodium salt pentahydrate (TA-2711). II. Distribution in the rat stomach”, J. Pharmacobiodyn.14(9), 547–554 (1991).
10.
ChanS.A.ChenM.J.LiuT.Y.FuhM.R.DengJ.F.WuM.L.HsiehS.J., “Determination of aristolochic acids in medicinal plant and herbal product by liquid chromatography-electrospray-ion trap mass spectrometry”, Talanta60, 679–685 (2003). doi: 10.1016/S0039-9140(03)00142-5
11.
YuX.CuiD.DavisM.R., “Identification of in vitro metabolites of indinavir by ‘intelligent automated LC-MS/MS’ (INTAMS) utilizing triple quadrupole tandem mass spectrometry”, J. Am. Soc. Mass Spectrom.10, 175–183 (1999). doi: 10.1016/S1044-0305(98)00132-9
12.
LamW.RamanathanR., “In electrospray ionization source hydrogen/deuterium exchange LC-MS and LC-MS/MS for characterization of metabolites”, J. Am. Soc. Mass Spectrom.13, 345–353 (2002). doi: 10.1016/S1044-0305(02)00346-X
13.
HolcapekM.KolarovaL.NobilisM., “High-performance liquid chromatography–tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites”, Anal. Bioanal. Chem.391, 59–78 (2008). doi: 10.1007/S00216-008-1962-7
14.
GanglE.UtkinH.GerberN.VourosP., “Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography–mass spectrometry”, J. Chromatogr. A974, 91–101 (2002). doi: 10.1016/S0021-9673(02)01243-8
15.
PengZ.H.SongW.HanF.M.ChenH.X.ZhuM.M.ChenY., “Chromatographic tandem mass spectrometric detection of papaverine and its major metabolites in rat urine”, Int. J. Mass Spectrom.266, 114–121 (2007). doi: 10.1016/j.ijms.2007.07.013
16.
MulderG.H.ScholtensE.MeuerD., “Collection of metabolites in bile and urine from rat”, Methods Enzymol.77, 21–30 (1981). doi: 10.1016/S0076-6879(81)77006-X
17.
RenL.BiK.S.GongP.ChengW.M.SongZ.FangL.ChenX.H., “Characterization of in vivo and in vitro metabolic profile of PAC-1 using liquid chromatography-mass spectrometry”, J. Chromatogr. B876, 47–53 (2008). doi: 10.1016/j.jchromb.2008.10.006
18.
PanJ.Y.ChengY.Y., “Identification and analysis of absorbed and metabolic components in rat plasma after oral administration of ‘Shuangdan’ granules by HPLC-DAD-ESI-MS/MS”, J. Pharm. Biomed. Anal.42, 565–572 (2006). doi: 10.1016/j.jpba.2006.05.006
19.
ZhangD.DuX.L.LiuM.Y.LiH.JiangY.ZhaoL.M.GuJ.K., “Determination of ecabet in human plasma by high-performance liquid chromatography–tandem mass spectrometry”, J. Chromatogr. B863, 223–228 (2008). doi: 10.1016/j.jchromb.2008.01.013
20.
ProefkeM.L.RinehartK.L., “Analysis of an Egyptian mummy resin by mass spectrometry”, J. Am. Soc. Mass Spectrom.3, 582–589 (1992). doi: 10.1016/1044-0305(92)85036-J
21.
ZhangZ.C.XuM.SunS.F.QiaoX.WangB.R.HanJ.GuoD.A., “Metabolic analysis of four phenolic acids in rat by liquid chromatography-tandem mass spectrometry”, J. Chromatogr. B871, 7–14 (2008). doi: 10.1016/j.jchromb.2008.06.019
22.
DaiH.X.WangM.M.LiX.R.WangL.J.LiY.H.XueM., “Structural elucidation of in vitro and in vivo metabolites of cryptotanshinone by HPLC–DAD–ESI–MSn”, J. Pharm. Biomed. Anal.48, 885–896 (2008). doi: 10.1016/j.jpba.2008.07.011
23.
UetrechtJ.P.TragerW., Drug Metabolism: Chemical and Enzymatic Aspects, Informa Healthcare USA, Inc., New York, USA, p. 71 (2007).
